- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
FDA Makes Plans to Correct Cancer Drug Shortages in the U.S.
Drug shortages in the U.S. have been an ongoing concern over the last couple of years, and have come to a head in recent months. Two cancer drugs in particular, Doxil (doxorubicin hydrochloride liposome injection) and the life-saving methotrexate are in short supply, but the FDA has made plans they say should swiftly reverse the situation.
Shortages of the medications worsened when a major manufacturing plant, Ben Venue Laboratories, shut down production due to safety concerns. To make up for the deficit, the FDA has decided to allow imports of a Doxil substitute, called Lipodox (doxorubicin hydrochloride liposome injection), which will apparently meet demand over the coming weeks. To address the methotrexate shortage, the Agency has approved another manufacturer to import a preservative-free generic version of the cancer drug to boost supplies.
Read the full story: http://hcp.lv/IJyGtG
Source: The Atlantic
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
